A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice

Nature Communications

Volumn 4, Issue , 2013, Pages

  Rössger, Katrin ^a   Charpin El Hamri, Ghislaine ^b   Fussenegger, Martin ^a,c  

^a ETH ZURICH   (Switzerland)

^b Institut Universitaire de Technologie   (France)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; FATTY ACID; LIPID; LIPID SENSING RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAMLINTIDE; UNCLASSIFIED DRUG;

DIET; DISEASE TREATMENT; DRUG; FAT; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ENGINEERING; HORMONE; LIPID; METABOLISM; OBESITY; PATHOLOGY; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSED LOOP SYNTHETIC GENE CIRCUIT; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GENE REGULATORY NETWORK; LIPID BLOOD LEVEL; LIPID DIET; MOUSE; NONHUMAN; OBESITY; PROMOTER REGION; WEIGHT REDUCTION;

MUS;

ANIMALS; DIET; FATTY ACIDS; FEMALE; GENE REGULATORY NETWORKS; GENES, SYNTHETIC; GENETIC THERAPY; MICE; OBESITY; PPAR ALPHA; TRANSGENES;

EID: 84889260345     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3825     Document Type: Article

References (54)

1. Rejeski, W. J. et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N. Engl. J. Med. 366, 1209-1217 (2012).
2. Haslam, D. W. & James, W. P. T. Obesity. Lancet 366, 1197-1209 (2005). (Pubitemid 41393598)
3. Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L. & Brown, M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378, 815-825 (2011).
4. Zhuo, Q., Yang, W., Chen, J. & Wang, Y. Metabolic syndrome meets osteoarthritis. Nat. Rev. Rheumatol. 8, 729-737 (2012).
5. Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C. & Harrold, J. A. Pharmacological management of appetite expression in obesity. Nat. Rev. Endocrinol. 6, 255-269 (2010).
6. Gray, L. J. et al. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes. Rev. 13, 483-498 (2012).
7. Khan, A. et al. Current updates in the medical management of obesity. Recent Pat. Endocr. Metab. Immune Drug Discov. 6, 117-128 (2012).
8. Mann, T. et al. Medicare's search for effective obesity treatments: diets are not the answer. Am. Psychol. 62, 220-233 (2007).
9. Lalmohamed, A. et al. Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study. BMJ 345, e5085 (2012).
10. Bays, H. E. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev. Cardiovasc. Ther. 9, 265-277 (2011).
11. Bray, G. A. Drug treatment of obesity. Rev. Endocr. Metab. Disord. 2, 403-418 (2001). (Pubitemid 33640589)
12. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007). (Pubitemid 46919772)
13. Ham, J. et al. Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptor d agonists as potent anti-obesity agents in vivo. Eur. J. Med. Chem. 53C, 190-202 (2012).
14. Bouchie, A. Regulatory fog lifts on obesity drugs. Nat. Biotechnol. 30, 810-811 (2012).
15. Hofbauer, K. G. & Nicholson, J. R. Pharmacotherapy of obesity. Exp. Clin. Endocrinol. Diabetes 114, 475-484 (2006). (Pubitemid 44870895)
16. Younk, L. M., Mikeladze, M. & Davis, S. N. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin. Pharmacother. 12, 1439-1451 (2011).
17. Singh-Franco, D., Robles, G. & Gazze, D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin. Ther. 29, 535-562 (2007). (Pubitemid 47016638)
18. Young, A. Tissue expression and secretion of amylin. Adv. Pharmacol. 52, 19-45 (2005). (Pubitemid 43588526)
19. Kumar, R. & Thompson, E. B. The structure of the nuclear hormone receptors. Steroids 64, 310-319 (1999). (Pubitemid 29284331)
20. Chinetti, G. et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7, 53-58 (2001). (Pubitemid 32095642)
21. Tien, E. S., Hannon, D. B., Thompson, J. T. & Vanden Heuvel, J. P. Examination of ligand-dependent coactivator recruitment by peroxisome proliferator-activated receptor-alpha (PPARalpha). PPAR. Res. 2006, 69612 (2006).
22. Vega, R. B., Huss, J. M. & Kelly, D. P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20, 1868-1876 (2000). (Pubitemid 30100203)
23. Daynes, R. A. & Jones, D. C. Emerging roles of ppars in inflammation and immunity. Nat. Rev. Immunol. 2, 748-759 (2002). (Pubitemid 37328715)
24. Stanley, T. B. et al. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. Biochemistry 42, 9278-9287 (2003). (Pubitemid 36959235)
25. Dowell, P. et al. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J. Biol. Chem. 274, 15901-15907 (1999).
26. Oberoi, J. et al. Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machinery. Nat. Struct. Mol. Biol. 18, 177-184 (2011).
27. Hanley, K. et al. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J. Clin. Invest. 100, 705-712 (1997). (Pubitemid 27340520)
28. Krey, G. et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11, 779-791 (1997). (Pubitemid 27225305)
29. Kersten, S., Desvergne, B. & Wahli, W. Roles of PPARs in health and disease. Nature 405, 421-424 (2000). (Pubitemid 30367411)
30. Gitzinger, M., Kemmer, C., El-Baba, M. D., Weber, W. & Fussenegger, M. Controlling transgene expression in subcutaneous implants using a skin lotion containing the apple metabolite phloretin. Proc. Natl Acad. Sci. USA 106, 10638-10643 (2009).
31. Terán, W., Krell, T., Ramos, J. L. & Gallegos, M.-T. Effector-repressor interactions, binding of a single effector molecule to the operator-bound TtgR homodimer mediates derepression. J. Biol. Chem. 281, 7102-7109 (2006). (Pubitemid 43847474)
32. Oresajo, C. et al. Protective effects of a topical antioxidant mixture containing vitamin C, ferulic acid, and phloretin against ultraviolet-induced photodamage in human skin. J. Cosmet. Dermatol. 7, 290-297 (2008).
33. Weber, W. et al. Macrolide-based transgene control in mammalian cells and mice. Nat. Biotechnol. 20, 901-907 (2002). (Pubitemid 35001127)
34. Soon-Shiong, P. Treatment of type I diabetes using encapsulated islets. Adv. Drug Deliv. Rev. 35, 259-270 (1999). (Pubitemid 29073618)
35. Orive, G. et al. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol. Ther. 12, 283-289 (2005). (Pubitemid 41025098)
36. Jacobs-Tulleneers-Thevissen, D. et al. Sustained function of alginateencapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 56, 1605-1614 (2013).
37. Duvivier-Kali, V. F., Omer, A., Parent, R. J., O'Neil, J. J. &Weir, G. C. Complete protection of islets against allorejection and autoimmunity by a simple bariumalginate membrane. Diabetes 50, 1698-1705 (2001). (Pubitemid 33641585)
38. Chang, T. M. S. Therapeutic applications of polymeric artificial cells. Nat. Rev. Drug Discov. 4, 221-235 (2005).
39. Mermier, P. & Baker, N. Flux of free fatty acids among host tissues, ascites fluid, and Ehrlich ascites carcinoma cells. J. Lipid Res. 15, 339-351 (1974).
40. Arab, L. Biomarkers of fat and fatty acid intake. J. Nutr. 133(Suppl 3): 925S-932S (2003).
41. Hegsted, D. M., McGandy, R. B., Myers, M. L. & Stare, F. J. Quantitative effects of dietary fat on serum cholesterol in man. Am. J. Clin. Nutr. 17, 281-295 (1965).
42. Keys, A., Anderson, J. T. & Grande., F. Serum cholesterol response to changes in the diet. IV. Particular saturated fatty acids in the diet. Metabolism 14, 376-387 (1965).
43. Kris-Etherton, P. M. & Yu, S. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am. J. Clin. Nutr. 65, 1628S-1644S (1997).
44. Lebovitz, H. E. Adjunct therapy for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6, 326-334 (2010).
45. Alper, H. & Weber, W. Building synthetic cell systems from the ground up. Curr. Opin. Biotechnol. 23, 641-643 (2012).
46. Wieland, M. & Fussenegger, M. Reprogrammed cell delivery for personalized medicine. Adv. Drug Deliv. Rev. 64, 1477-1487 (2012).
47. Ruder, W. C., Lu, T. & Collins, J. J. Synthetic biology moving into the clinic. Science 333, 1248-1252 (2011).
48. Khalil, A. S. & Collins, J. J. Synthetic biology: applications come of age. Nat. Rev. Genet. 11, 367-379 (2010).
49. Orive, G. et al. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol. 22, 87-92 (2004). (Pubitemid 38130176)
50. Catena, R. et al. Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system. J. Control. Release 146, 93-98 (2010).
51. Ausla?nder, S., Wieland, M. & Fussenegger, M. Smart medication through combination of synthetic biology and cell microencapsulation. Metab. Eng. 14, 252-260 (2012).
52. Fischbach, M. A., Bluestone, J. A. & Lim, W. A. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med. 5, 179ps177 (2013).
53. Simonsen, J. L. et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat. Biotechnol. 20, 592-596 (2002). (Pubitemid 34595153)
54. Schlatter, S., Rimann, M., Kelm, J. & Fussenegger, M. SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus alphaamylase. Gene 282, 19-31 (2002). (Pubitemid 34117558)